Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
Danish A, Della Pia A, Fogel L, Alkhatatneh H, Zhao C, Varughese T, Al Feghali KA, Pascual L, Sinclaire B, Marafelias M, Zenreich J, Kuo YH, Feldman TA, Zhang Y, Goy AH, Ip A, Rowley SD. Danish A, et al. Among authors: zenreich j. Front Oncol. 2024 Aug 19;14:1425506. doi: 10.3389/fonc.2024.1425506. eCollection 2024. Front Oncol. 2024. PMID: 39228984 Free PMC article.
Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.
Zolotov E, Kabat M, Parmar H, Anand P, Zenreich J, Aleman A, Phull P, Doucette K, Vesole DH, Siegel DS, Biran N. Zolotov E, et al. Among authors: zenreich j. Leuk Lymphoma. 2024 Dec;65(13):2000-2008. doi: 10.1080/10428194.2024.2385501. Epub 2024 Jul 31. Leuk Lymphoma. 2024. PMID: 39082756
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A, Petrillo A, Della Pia A, Lee GG, Gill S, Varughese T, Zenreich J, Gutierrez M, Zhang J, Ahn J, Bharani V, Nejad AS, Pascual L, Feldman TA, Leslie LA, Goy AH. Ip A, et al. Among authors: zenreich j. Leuk Lymphoma. 2023 Dec;64(14):2225-2235. doi: 10.1080/10428194.2023.2259528. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37740588 Free article. Clinical Trial.
Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Fanning SL, Korngold R, Yang Z, Goldgirsh K, Park S, Zenreich J, Baker M, McKiernan P, Tan M, Zhang B, Donato ML, Perlin DS. Fanning SL, et al. Among authors: zenreich j. PLoS Pathog. 2021 Oct 29;17(10):e1010025. doi: 10.1371/journal.ppat.1010025. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34714894 Free PMC article.
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Biran N, Gourna Paleoudis E, Feinman R, Vesole DH, Zenreich J, Wang S, Ahn J, Bansal M, Rowley S, Donato M, Pecora AL, Richter J, Anand P, McBride L, Ivanovski K, Korngold R, Siegel DS. Biran N, et al. Among authors: zenreich j. Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17. Am J Hematol. 2021. PMID: 34435374 Free article. Clinical Trial. No abstract available.
Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
Skarbnik AP, Donato ML, Feinman R, Rowley SD, Vesole DH, Goy AH, Munshi PN, Feldman T, Leslie LA, Biran N, Nyirenda T, Fields PA, Descalzi-Montoya D, Zenreich J, Korngold R, Pecora AL. Skarbnik AP, et al. Among authors: zenreich j. Transplant Cell Ther. 2021 May;27(5):391-403. doi: 10.1016/j.jtct.2020.12.026. Epub 2020 Dec 30. Transplant Cell Ther. 2021. PMID: 33965177 Free article. Clinical Trial.
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Donato ML, Park S, Baker M, Korngold R, Morawski A, Geng X, Tan M, Ip A, Goldberg S, Rowley S, Chow K, Brown E, Zenreich J, McKiernan P, Buttner K, Ullrich A, Long L, Feinman R, Ricourt A, Kemp M, Vendivil M, Suh H, Balani B, Cicogna C, Sebti R, Al-Khan A, Sperber S, Desai S, Fanning S, Arad D, Go R, Tam E, Rose K, Sadikot S, Siegel D, Gutierrez M, Feldman T, Goy A, Pecora A, Biran N, Leslie L, Gillio A, Timmapuri S, Boonstra M, Singer S, Kaur S, Richards E, Perlin DS. Donato ML, et al. Among authors: zenreich j. JCI Insight. 2021 Mar 22;6(6):e143196. doi: 10.1172/jci.insight.143196. JCI Insight. 2021. PMID: 33571168 Free PMC article. Clinical Trial.
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A. Mato AR, et al. Among authors: zenreich j. Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25691474 Free article. Clinical Trial.